$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

IFF beat Q2 FY2025 estimates with strong Food Ingredients margins and new buyback, but Scent and Health & Biosciences headwinds temper the outlook.

# IFF Delivers Q2 FY2025 Beats on Revenue and EPS, but Segment Divergence and Health Headwinds Temper Outlook

---

## Executive Summary

- **International Flavors & Fragrances (IFF) reported Q2 FY2025 net sales of $2.764B and adjusted EPS of $1.15, both beating consensus estimates by 2.5% and 2.7%, respectively.** However, year-over-year sales declined by 4.3%, and adjusted EPS was slightly down, reflecting ongoing top-line and margin pressures in certain segments.
- **Earnings quality was mixed:** While overall adjusted operating EBITDA margin held steady at 20.0%, the Food Ingredients segment delivered a notable margin expansion (+1.7pp YoY), offsetting margin compression in the Scent segment (-2.1pp YoY). Cost discipline and portfolio optimization, including divestitures, were key contributors to the quarter’s resilience.
- **Management maintained a confident and proactive tone, reaffirming full-year guidance** and announcing a new $500M share repurchase program. However, they flagged continued weakness in the Health & Biosciences sub-segment and ongoing regulatory and FX headwinds as areas of caution.
- **Risks remain around Scent margin compression, Health & Biosciences softness, and regulatory costs,** but upside potential exists in Food Ingredients margin expansion, cost controls, and capital return initiatives. Improved leverage (net debt/EBITDA at 2.5x) further supports the balance sheet.
- **Catalyst watch:** Near-term, the market is likely to react modestly positively to the headline beats and capital return news, but investor focus will remain on segment-level performance and execution on cost and portfolio initiatives. Key catalysts include Q3 results, further divestiture updates, and progress in Health & Biosciences stabilization.

---

## Performance Snapshot

| Metric                | Reported | Consensus | Surprise | YoY Change |
|-----------------------|----------|-----------|----------|------------|
| Revenue               | $2.764B  | $2.697B   | +2.5%    | -4.3%      |
| Adjusted EPS          | $1.15    | $1.12     | +2.7%    | Slightly ↓ |
| Adj. Operating EBITDA | $553M    | N/A       | N/A      | Flat       |
| EBITDA Margin         | 20.0%    | N/A       | N/A      | Flat       |
| Food Ingredients EBITDA Margin | 14.6% | N/A | N/A | +1.7pp      |
| Scent EBITDA Margin   | 21.6%    | N/A       | N/A      | -2.1pp     |

---

## Earnings Quality

IFF’s Q2 FY2025 results reflect **solid cost discipline and portfolio optimization** rather than organic volume growth. The company’s **flat overall EBITDA margin (20.0%) masks significant divergence**: Food Ingredients saw a strong margin lift, while Scent margins compressed. Cost controls and divestitures (notably in Pharma Solutions and Nitrocellulose) helped offset persistent restructuring and regulatory costs. The company’s ability to maintain margins despite sales declines demonstrates underlying operational resilience, but the lack of volume growth and segment-level pressures warrant caution.

---

## Management Commentary & Guidance

Management’s tone was **confident and forward-looking**, emphasizing strategic portfolio optimization, disciplined capital allocation, and a new $500M share repurchase program. **Full-year FY2025 guidance was reaffirmed**: sales of $10.6B–$10.9B and adjusted EBITDA of $2.0B–$2.15B, in line with Street expectations. Guidance assumes currency-neutral sales growth of 1–4% and EBITDA growth of 5–10%. However, management flagged continued weakness in Health & Biosciences for H2 and ongoing regulatory and FX headwinds, suggesting a balanced but cautious outlook.

---

## Key Risks

- **Segment margin pressures:** Scent margin compression and Health & Biosciences weakness could weigh on near-term results.
- **Regulatory and restructuring costs:** Elevated costs remain a drag on profitability.
- **FX volatility:** Currency headwinds may persist into H2.
- **Execution risk:** Delivering on portfolio optimization and cost control targets is critical.

---

## Expected Market Reaction

Analyst and investor sentiment is likely to be **modestly positive** given the headline beats, improved leverage, and capital return initiatives. However, the market may remain cautious until there is clearer evidence of stabilization in Health & Biosciences and margin recovery in Scent. The focus will be on execution and segment-level trends in upcoming quarters.

---

## Final Takeaway

IFF delivered a **resilient but mixed quarter**: headline beats and strong Food Ingredients margin expansion were offset by Scent margin compression and Health & Biosciences headwinds. The market may be underestimating the positive impact of cost controls and portfolio actions, but risks remain around segment-specific challenges and regulatory costs. **Key upcoming catalysts** include Q3 results, further divestiture progress, and updates on Health & Biosciences performance. Overall, IFF’s Q2 FY2025 results support a cautiously optimistic outlook, with execution on cost and portfolio initiatives critical for sustained upside.

IFF Q2: Margin Strength Amid Segment Headwinds

IFF is showing early signs of revenue stabilization and margin recovery for Q2 2025, driven by innovation and cost discipline, though FX and tariff risks remain underappreciated by the market.

# International Flavors & Fragrances Inc. (IFF): Innovation-Led Stabilization and Margin Recovery in Focus for Q2 2025

## Executive Summary: Bullish Outlook on Innovation and Margin Recovery, with FX Risks Underappreciated

We hold a **Bullish** view on International Flavors & Fragrances Inc. (IFF) for Q2 2025, driven by sequential revenue stabilization, margin recovery, and the early impact of innovation and geographic expansion initiatives. **Q1 2025 revenue of $2.84B** (–1.93% YoY, but up sequentially) and **gross margin improvement of +110 bps YoY to 36.4%** set a constructive baseline. Management’s disciplined execution and reaffirmed FY2025 guidance (sales of $10.60B–$10.90B) support our expectation for a modest Q2 revenue uptick and further margin gains. However, the market may be underestimating the **persistent FX and tariff headwinds** (–2% to sales, –3% to EBITDA) that could temper upside if not offset by innovation-driven growth.

## Recent Trends Signal What’s Next: Sequential Stabilization and Margin Recovery

Recent quarters reveal a pattern of stabilization and early recovery. **Q1 2025 revenue of $2.84B** marked a sequential improvement from Q4, with Taste (+1% sales) and Health & Biosciences (+2%) offsetting Food Ingredients (–7%). **Gross margin rose to 36.4% (+110 bps YoY)**, reflecting early benefits from cost initiatives and mix improvement. Operating margin remains pressured by prior impairments, but the trend is positive.

### Revenue, Margin, and EPS Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------------|---------|
| Q2 2024      | 2.87         | 35.1             | 10.2                 | 6.8           | 1.18    |
| Q3 2024      | 2.81         | 35.5             | 10.5                 | 7.0           | 1.15    |
| Q4 2024      | 2.78         | 35.3             | 9.8                  | 6.5           | 1.10    |
| Q1 2025      | 2.84         | 36.4             | 10.7                 | 7.2           | 1.20    |

**Key trend:** Revenue and margins are stabilizing, with Q1 2025 showing the first sequential uptick in both revenue and gross margin in four quarters.

## Management’s Forward Tone and Positioning: Cautious Optimism with Focus on Execution

Management’s Q1 2025 commentary was notably more confident than in prior quarters, emphasizing “solid results” and “disciplined execution.” The CEO stated, **“We’re seeing early signs of normalization in demand and are confident our innovation pipeline will support growth in the second half.”** This is a shift from Q4’s more defensive tone, which focused on “navigating macro uncertainty.” The explicit reaffirmation of FY2025 guidance and acknowledgment of FX/tariff risks signal a balanced but constructive outlook.

## KPI Trends & Upcoming Quarter Drivers: Innovation, Working Capital, and Short Interest

The most relevant KPIs for Q2 2025 are:

- **Working Capital:** Q1 saw increased inventories and receivables, with working capital up 4% QoQ. This could pressure free cash flow in Q2, but also supports future sales.
- **Capex and Innovation:** Capex of **$179M in Q1** (up 12% YoY) reflects investment in new facilities (Singapore, Hyderabad) and product launches (e.g., CHOOZIT® LIFT).
- **Short Interest:** Short interest declined to **2.82%** (–5.37% QoQ), indicating reduced bearish sentiment.

### KPI Movement Table

| KPI                | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|--------------------|---------|---------|---------|------------|------------|
| Working Capital ($B)| 2.10    | 2.18    | 2.27    | +8%        | +4%        |
| Capex ($M)         | 160     | 170     | 179     | +12%       | +5%        |
| Short Interest (%) | 3.10    | 2.98    | 2.82    | –9%        | –5.37%     |

**Impact:** Elevated working capital may weigh on Q2 cash flow, but innovation investments are likely to support revenue and margin stabilization.

## Missed by the Street: Strategic Divestiture and Leaner Structure

A key overlooked signal is the **timing and impact of the Pharma Solutions divestiture**. Management described it as “critical for debt reduction,” and proceeds are already factored into FY guidance. However, the full benefit of a leaner operating structure and lower interest expense is not yet reflected in consensus Q2 estimates. This could provide upside surprise on both margin and EPS.

## Scenarios for the Upcoming Quarter: Bull, Base, and Bear Cases

### Scenario Table

| Scenario | Revenue ($B) | EPS ($) | Operating Margin (%) | Key Assumptions                                      |
|----------|--------------|---------|----------------------|------------------------------------------------------|
| Bull     | 2.90         | 1.28    | 37.5                 | Innovation uptake, easing FX, strong execution        |
| Base     | 2.85         | 1.23    | 36.7                 | Steady execution, muted tariff/FX impact             |
| Bear     | 2.80         | 1.10    | 35.8                 | Persistent FX/tariff headwinds, working capital drag  |

**Most likely scenario:** The **Base case** is most probable, given current evidence of sequential stabilization, management’s reaffirmed guidance, and ongoing FX/tariff risks.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q2 2024      | 2.87         | 1.18    | 35.1             | 10.2                 |
| Q3 2024      | 2.81         | 1.15    | 35.5             | 10.5                 |
| Q4 2024      | 2.78         | 1.10    | 35.3             | 9.8                  |
| Q1 2025      | 2.84         | 1.20    | 36.4             | 10.7                 |

### KPI Movement Table

| KPI                | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|--------------------|---------|---------|---------|------------|------------|
| Working Capital ($B)| 2.10    | 2.18    | 2.27    | +8%        | +4%        |
| Capex ($M)         | 160     | 170     | 179     | +12%       | +5%        |
| Short Interest (%) | 3.10    | 2.98    | 2.82    | –9%        | –5.37%     |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand and are confident our innovation pipeline will support growth in the second half.”**  
   – Q1 2025 Earnings Call  
   *Interpretation: Management expects demand recovery and innovation to drive H2 growth, supporting Q2 stabilization.*

2. **“Disciplined execution and cost initiatives are beginning to show in our margin performance.”**  
   – Q1 2025 Earnings Call  
   *Interpretation: Margin recovery is underway, with further improvement likely if execution continues.*

3. **“FX and tariff headwinds remain a challenge, with a 2% impact to sales and 3% to EBITDA expected for the year.”**  
   – Q1 2025 Earnings Call  
   *Interpretation: Currency and trade risks are material and could limit upside if not offset.*

4. **“The divestiture of Pharma Solutions was critical for debt reduction and streamlining our portfolio.”**  
   – Q1 2025 Earnings Call  
   *Interpretation: Leaner structure and lower interest expense may benefit Q2 margins and EPS.*

5. **“We continue to invest in innovation centers in Singapore and Hyderabad to drive future growth.”**  
   – Q1 2025 Earnings Call  
   *Interpretation: Capex is focused on long-term topline and margin expansion.*

6. **“Inventory and receivables increased in Q1, reflecting both higher input costs and preparation for new product launches.”**  
   – Q1 2025 10-Q  
   *Interpretation: Working capital build may pressure near-term cash flow, but supports future sales.*

7. **“We are reaffirming our full-year 2025 guidance of $10.60B–$10.90B in sales.”**  
   – Q1 2025 Earnings Call  
   *Interpretation: Management’s confidence in execution and demand visibility for the remainder of the year.*

---

**Bottom Line:** IFF’s Q2 2025 outlook is underpinned by sequential revenue and margin stabilization, disciplined execution, and early returns from innovation investments. While FX and working capital trends warrant close monitoring, the company’s leaner structure and innovation pipeline position it for modest upside relative to consensus.

IFF: Innovation Drives Margin Recovery for Q2 2025